Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:CASNumber |
1623267-97-0
|
| gptkbp:hasApplication |
preclinical studies
|
| gptkbp:hasMolecularFormula |
C19H10ClN5OS
|
| gptkbp:hasSMILES |
C1=CC2=C(C=C1C#N)C(=O)N(C2=O)C3=NC4=C(S3)C=CC(=C4)Cl
|
| https://www.w3.org/2000/01/rdf-schema#label |
MLi-2
|
| gptkbp:inhibitedBy |
gptkb:LRRK2
|
| gptkbp:IUPACName |
(3Z)-3-[(6-chloro-7H-benzo[d]imidazo[2,1-b][1,3]thiazin-2-yl)methylene]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile
|
| gptkbp:mechanismOfAction |
selective LRRK2 kinase inhibitor
|
| gptkbp:PubChem_CID |
121304016
CHEMBL3823101 |
| gptkbp:synonym |
MLi2
|
| gptkbp:usedFor |
research tool in Parkinson's disease
|
| gptkbp:bfsParent |
gptkb:LRRK2
|
| gptkbp:bfsLayer |
7
|